Agendia Genomic Tests (MammaPrint, BluePrint & TargetPrint) Among Highlights of San Antonio Breast Cancer Symposium
Podium Presentations and Ten Scientific Posters Focus Cancer MDs’ Attention Read More
Agendia Announces Presentation of Data Highlighting Symphony Suite of Genomic tests (MammaPrint, BluePrint, and TargetPrint) at San Antonio Breast Cancer Symposium
Ten Scientific Posters Document Study Results on Second-Generation Symphony Suite, Read More
Multiple International Breast Cancer Guidelines Confirm Use of Agendia Tests for Prognostic, Predictive Information in Cancer Treatment Decisions
Important Role of Molecular Subtyping in Determining the Need for Read More
Researchers Identify Splice Variant of Breast Cancer Gene that Can Mask Risk of Recurrence
‘High Risk’ Patients with Unusual Hormone Receptors May Be Undertreated Read More
Molecular Subtyping Can Help Determine Prognosis and Chemotherapy Benefit in Colorectal Cancer Patients
CHICAGO – Molecular subtyping can help predict outcomes and chemotherapy Read More
Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
IRVINE, CA, May 31, 2013 – Agendia, a world leader Read More
Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
IRVINE, CA, May 2, 2013 – Agendia, a world leader Read More
Study shows half of early-stage breast cancer patients may be able to avoid chemotherapy
Agendia Announces Launch of ColoPrint for Colon Cancer Prognosis and Prediction
MammaPrint breast cancer test ID’s women who can avoid chemotherapy
KARE, Minneapolis-St.Paul-2013 This TV report tells how you can “know Read More
Study Shows Half of Early-Stage Breast Cancer Patients May Safely Avoid Chemotherapy
IRVINE, CA and AMSTERDAM, THE NETHERLANDS, February 4, 2013 – Read More
